{"transactions":[{"id":3973130,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T20:01:14.000Z","date":"2018-03-30","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":64049,"source":{"system":"sec-edgar","filing":"0001213900-18-003977","document":"f4033018bacha_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390018003977/f4033018bacha_delmar.xml","form_type":"4"}},{"id":4112188,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"grant","acquired":true,"shares":93600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":93600,"derivative":{"exercise_price":4.95,"exercise_date":"2017-12-22","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":93600},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112187,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"disposition_to_issuer","acquired":false,"shares":93600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":0,"derivative":{"exercise_price":4.95,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":93600},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112186,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"grant","acquired":true,"shares":87500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":87500,"derivative":{"exercise_price":4.2,"exercise_date":"2017-12-22","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112185,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"disposition_to_issuer","acquired":false,"shares":87500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2023-08-15","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112184,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"grant","acquired":true,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":37500,"derivative":{"exercise_price":2,"exercise_date":"2017-12-22","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112183,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-22","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of \"old\" options and the grant of replacement options resulting from the foregoing amendments to the options."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2022-02-01","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4112182,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:59:18.000Z","date":"2017-12-31","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":63873,"source":{"system":"sec-edgar","filing":"0000905718-18-000015","document":"bacha_form4dec222017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571818000015/bacha_form4dec222017.xml","form_type":"4"}},{"id":4189109,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-10-10T12:10:21.000Z","date":"2017-10-06","kind":"purchase","acquired":true,"shares":2450,"price":0.88,"value":2156.0,"ownership":{"direct":true},"balance_after":63697,"source":{"system":"sec-edgar","filing":"0001213900-17-010402","document":"f4100617bacha_delmarpharm.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017010402/f4100617bacha_delmarpharm.xml","form_type":"4"}},{"id":4189108,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-10-10T12:10:21.000Z","date":"2017-10-06","kind":"purchase","acquired":true,"shares":7550,"price":0.87,"value":6568.5,"ownership":{"direct":true},"balance_after":61247,"source":{"system":"sec-edgar","filing":"0001213900-17-010402","document":"f4100617bacha_delmarpharm.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017010402/f4100617bacha_delmarpharm.xml","form_type":"4"}},{"id":4197776,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-10-02T23:55:57.000Z","date":"2017-09-29","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":53697,"source":{"system":"sec-edgar","filing":"0001213900-17-010216","document":"f4092917bacha_delmarpharm.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017010216/f4092917bacha_delmarpharm.xml","form_type":"4"}},{"id":4264458,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-07-05T18:23:04.000Z","date":"2017-06-30","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":53521,"source":{"system":"sec-edgar","filing":"0001213900-17-007139","document":"f4063017bacha_delmarpharma.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017007139/f4063017bacha_delmarpharma.xml","form_type":"4"}},{"id":4271063,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-06-28T15:29:05.000Z","date":"2017-06-26","kind":"purchase","acquired":true,"shares":6700,"price":3.6,"value":24120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $32,160. Reported price is based on exchange rate of 0.75."}],"balance_after":53345,"source":{"system":"sec-edgar","filing":"0001213900-17-006878","document":"f4062617bacha_delmarpharma.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017006878/f4062617bacha_delmarpharma.xml","form_type":"4"}},{"id":4291083,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-06-06T21:12:18.000Z","date":"2017-06-06","kind":"purchase","acquired":true,"shares":5000,"price":2.12,"value":10600.0,"ownership":{"direct":true},"balance_after":46645,"source":{"system":"sec-edgar","filing":"0001213900-17-006196","document":"f4060617bacha_delmarpharma.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017006196/f4060617bacha_delmarpharma.xml","form_type":"4"}},{"id":4330153,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-05-08T20:58:18.000Z","date":"2017-05-05","kind":"purchase","acquired":true,"shares":2500,"price":2.2,"value":5500.0,"ownership":{"direct":true},"balance_after":41645,"source":{"system":"sec-edgar","filing":"0001213900-17-004749","document":"f4050517bacha_delmarpharma.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017004749/f4050517bacha_delmarpharma.xml","form_type":"4"}},{"id":4361272,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:22:01.000Z","date":"2017-03-31","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":39145,"source":{"system":"sec-edgar","filing":"0001213900-17-003327","document":"f4033117bacha_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017003327/f4033117bacha_delmar.xml","form_type":"4"}},{"id":4431585,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options (Right to Buy)","published_at":"2017-02-22T21:24:33.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":93600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in equal monthly installments over three years."}],"balance_after":93600,"derivative":{"exercise_price":4.95,"exercise_date":"2020-02-17","expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":93600},"source":{"system":"sec-edgar","filing":"0001213900-17-001711","document":"f4021717bacha_delmarpharma.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017001711/f4021717bacha_delmarpharma.xml","form_type":"4"}},{"id":4471171,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-02-02T16:44:11.000Z","date":"2017-02-01","kind":"purchase","acquired":true,"shares":4000,"price":5,"value":20000.0,"ownership":{"direct":true},"balance_after":38969,"source":{"system":"sec-edgar","filing":"0001213900-17-000873","document":"f4020117bacha_delamar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017000873/f4020117bacha_delamar.xml","form_type":"4"}},{"id":4507884,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-01-03T18:57:24.000Z","date":"2016-12-31","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":34969,"source":{"system":"sec-edgar","filing":"0001213900-17-000025","document":"f4123116bacha_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390017000025/f4123116bacha_delmar.xml","form_type":"4"}},{"id":4584402,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":167816,"kind":"person","name":"BACHA JEFFREY","position":1,"cik":"0001432149","reported_name":"BACHA JEFFREY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2016-10-05T18:14:40.000Z","date":"2016-10-03","kind":"other","acquired":true,"shares":176,"price":3.2,"value":563.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":34793,"source":{"system":"sec-edgar","filing":"0001213900-16-017306","document":"f4100316bacha_delmar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390016017306/f4100316bacha_delmar.xml","form_type":"4"}}]}